UNCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Unicycive Therapeutics Inc (UNCY) is not a strong buy at this moment for a beginner investor with a long-term horizon. While there are positive catalysts such as upcoming FDA review and potential market launch of a key drug, the company's financial performance is weak, and there are no immediate trading signals or strong technical indicators suggesting a favorable entry point. The stock's recent price movement and lack of significant insider or hedge fund activity further support a cautious approach.
The MACD is slightly positive and expanding, indicating mild upward momentum. RSI is neutral at 58.174, and moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 7.238) but has not broken through. Overall, the technical indicators suggest a lack of strong directional momentum.
The company has sufficient resources to fund operations into 2027.
The company reported a fiscal year GAAP EPS of -$1.67, missing expectations. Financial performance is weak, with net income and EPS showing significant declines YoY. There are no significant insider or hedge fund trading trends, and the stock's recent price movement has been negative.
In 2025/Q4, revenue remained at 0 with no YoY growth. Net income dropped by -31.86% YoY to -$14.67 million, and EPS fell by -66.67% YoY to -$0.68. The company has a cash position of $54.9 million, sufficient to fund operations into 2027.
Analysts maintain a Buy rating but have lowered price targets recently (e.g., Guggenheim reduced the target from $46 to $40). WestPark Capital initiated coverage with a Buy rating and a $72 price target, citing a compelling investment case due to upcoming catalysts such as FDA approval and reimbursement support.
